QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.077974v1 312/3/875    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Le Foll, B. Articles by Goldberg, S. R. Search for Related Content PubMed PubMed Citation Articles by Le Foll, B. Articles by Goldberg, S. R.

PERSPECTIVES IN PHARMACOLOGY

Cannabinoid CB₁ Receptor Antagonists as Promising New Medications for Drug Dependence

Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland

This review examines the development of cannabinoid CB₁ receptor antagonists as a new class of therapeutic agents for drug addiction. Abused drugs [alcohol, opiates, ⁹-tetrahydrocannabinol (⁹-THC), and psychostimulants, including nicotine] elicit a variety of chronically relapsing disorders by interacting with endogenous neural pathways in the brain. In particular, they share the common property of activating mesolimbic dopamine brain reward systems, and virtually all abused drugs elevate dopamine levels in the nucleus accumbens. Cannabinoid CB₁ receptors are expressed in this brain reward circuit and modulate the dopamine-releasing effects of ⁹-THC and nicotine. Rimonabant (SR141716), a CB₁ receptor antagonist, blocks both the dopamine-releasing and discriminative and rewarding effects of ⁹-THC in animals. Blockade of CB₁ receptor activity by genetic invalidation also decreases rewarding effects of opiates and alcohol in animals. Although CB₁ receptor blockade is generally ineffective in reducing the self-administration of cocaine in rodents and primates, it reduces the reinstatement of extinguished cocaine-seeking behavior produced by cocaine-associated conditioned stimuli and cocaine-priming injections. Likewise, CB₁ receptor blockade is effective in reducing nicotine-seeking behavior induced by re-exposure to nicotine-associated stimuli. Some of these findings have been recently validated in humans. In clinical trials, Rimonabant blocks the subjective effects of ⁹-THC in humans and prevents relapse to smoking in exsmokers. Findings from both clinical and preclinical studies suggest that ligands blocking CB₁ receptors offer a novel approach for patients suffering from drug dependence that may be efficacious across different classes of abused drugs.

Address correspondence to: Dr. Bernard Le Foll, Preclinical Pharmacology Section, NIDA, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224. E-mail: blefoll{at}intra.nida.nih.gov

This article has been cited by other articles:

				A. Strougo, L. Zuurman, C. Roy, J. Pinquier, J. van Gerven, A. Cohen, and R. Schoemaker Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids J Psychopharmacol, September 1, 2008; 22(7): 717 - 726. [Abstract] [PDF]

				D. L. McKinney, M. P. Cassidy, L. M. Collier, B. R. Martin, J. L. Wiley, D. E. Selley, and L. J. Sim-Selley Dose-Related Differences in the Regional Pattern of Cannabinoid Receptor Adaptation and in Vivo Tolerance Development to {Delta}9-Tetrahydrocannabinol J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 664 - 673. [Abstract] [Full Text] [PDF]

				B. Le Foll MD PhD and T. P. George MD Treatment of tobacco dependence: integrating recent progress into practice Can. Med. Assoc. J., November 20, 2007; 177(11): 1373 - 1380. [Abstract] [Full Text] [PDF]

				S. Caille, L. Alvarez-Jaimes, I. Polis, D. G. Stouffer, and L. H. Parsons Specific Alterations of Extracellular Endocannabinoid Levels in the Nucleus Accumbens by Ethanol, Heroin, and Cocaine Self-Administration J. Neurosci., April 4, 2007; 27(14): 3695 - 3702. [Abstract] [Full Text] [PDF]

				H. Dermatis and M. Galanter Clinical Advances in Pharmacological and Integrated Treatment Approaches for Alcohol and Drug Use Disorders Focus, January 1, 2007; 5(2): 141 - 150. [Abstract] [Full Text] [PDF]

				J. Ellis, J. D. Pediani, M. Canals, S. Milasta, and G. Milligan Orexin-1 Receptor-Cannabinoid CB1 Receptor Heterodimerization Results in Both Ligand-dependent and -independent Coordinated Alterations of Receptor Localization and Function J. Biol. Chem., December 15, 2006; 281(50): 38812 - 38824. [Abstract] [Full Text] [PDF]

				A. Baker, R. Richmond, M. Haile, T. J. Lewin, V. J. Carr, R. L. Taylor, S. Jansons, and K. Wilhelm A Randomized Controlled Trial of a Smoking Cessation Intervention Among People With a Psychotic Disorder Am J Psychiatry, November 1, 2006; 163(11): 1934 - 1942. [Abstract] [Full Text] [PDF]

				P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]

				S. A. Moore, G. G. Nomikos, A. K. Dickason-Chesterfield, D. A. Schober, J. M. Schaus, B.-P. Ying, Y.-C. Xu, L. Phebus, R. M. A. Simmons, D. Li, et al. From The Cover: Identification of a high-affinity binding site involved in the transport of endocannabinoids PNAS, December 6, 2005; 102(49): 17852 - 17857. [Abstract] [Full Text] [PDF]